Whether you are a new T1D Family, a TrialNet participant, a healthcare provider, or a researcher — you'll find resources here.
We’re here to help you after a new T1D diagnosis. Get answers to frequently asked questions and learn about clinical studies testing ways to maintain insulin production.
While you wait for screening results, get answers to your questions, find out about next steps, and learn more about TrialNet’s Pathway to Prevention.
Your T1D families are important to you. Learn how easy it is to connect your patients with world-class T1D research.
Endocrinology Services Northwest
929 SW Simpson Ave, Ste 220, Bend, OR 97702
St. Vincent Healthcare Diabetes Center
2900 12th Ave North, STE 10 West, Billings, MT 59101
Billings Clinic Diabetes Center
801 N 29th St, Billings, MT 59101
St. Lukes Humphreys Diabetes Center
701 E. Morrison Knudsen Dr, Suite 100, Boise, ID 83712
Rocky Mountain Diabetes and Osteoporosis Center, PA
3910 Washington Parkway, Idaho Falls, ID 83404
Oregon Health Sciences University
3181 SW Sam Jackson Park Rd, OP05-DC, Portland, OR 97239
Legacy Emanuel Childrens Hospital
501 N. Graham St Ste 375, Portland, OR 97227
Kadlec Medical Center Diabetes Learning Center
888 Swift Blvd, Richland, WA 99352
Childrens Hospital & Regional Medical Center
1900 Ninth Ave, M/S JMB-9C, Seattle, WA 98101
Sacred Heart Medical Center
105 W. 8th Ave., Spokane, WA 99204
If you have a relative with T1D, you’re in a unique position to help us learn more about the disease and how to stop it. The first step is to sign up for Pathway to Prevention screening to determine your risk of developing T1D.
TrialNet is testing the drug abatacept to see if it can delay or prevent progression of early stage T1D (stage 1 to stage 2) and ultimately prevent clinical diagnosis (stage 3). In earlier studies for people newly diagnosed (stage 3), abatacept helped slow down disease progression.
We are testing the drug hydroxychloroquine (HCQ) to see if it can delay or prevent early stage T1D (stage 1) from progressing to abnormal glucose tolerance (stage 2) and ultimately prevent clinical diagnosis (stage 3). HCQ is already used to reduce symptoms and progression of other autoimmune diseases, such as rheumatoid arthritis and lupus. This is the first study to see if it can prevent or delay T1D.
Once your study ends, we're still here for you. Participant monitoring and continued involvement helps us learn more about T1D.